Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Journal: British journal of haematology
Published: January 30, 2024
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 01, 2023
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 15, 2023
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
Journal: Leukemia & lymphoma
Published: February 17, 2023
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Journal: Leukemia & lymphoma
Published: December 08, 2022
Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.
Journal: Blood advances
Published: September 20, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Journal: Blood advances
Published: September 24, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Journal: British journal of haematology
Published: September 20, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
Journal: Blood advances
Published: July 01, 2021
Last Updated: 09/26/2026